Open AccessMitochondria-acting carrier-free nanoplatform self-assembled by α-tocopheryl succinate carrying cisplatin for combinational tumor therapy
Author(s) -
Heng Mei,
Jing Li,
Shengsheng Cai,
Xuequan Zhang,
Wei Shi,
Hai Zhu,
Jun Cao,
Bin He
Publication year - 2021
Publication title -
regenerative biomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.166
H-Index - 25
ISSN - 2056-3426
DOI - 10.1093/rb/rbab029
Subject(s) - cisplatin , chemistry , mitochondrion , reactive oxygen species , apoptosis , drug , nanomedicine , conjugate , drug carrier , in vitro , biophysics , drug delivery , intracellular , nanotechnology , nanoparticle , cancer research , chemotherapy , pharmacology , biochemistry , materials science , biology , mathematical analysis , genetics , mathematics , organic chemistry
Unsatisfactory drug loading capability, potential toxicity of the inert carrier and the limited therapeutic effect of a single chemotherapy drug are all vital inhibitory factors of carrier-assisted drug delivery systems for chemotherapy. To address the above obstacles, a series of carrier-free nanoplatforms self-assembled by dual-drug conjugates was constructed to reinforce chemotherapy against tumors by simultaneously disrupting intratumoral DNA activity and inhibiting mitochondria function. In this nanoplatform, the mitochondria-targeting small-molecular drug, α-tocopheryl succinate (TOS), firstly self-assembled into nanoparticles, which then were used as the carrier to conjugate cisplatin (CDDP). Systematic characterization results showed that this nanoplatform exhibited suitable particle size and a negative surface charge with good stability in physicochemical environments, as well as pH-sensitive drug release and efficient cellular uptake. Due to the combined effects of reactive oxygen species (ROS) generation by TOS and DNA damage by CDDP, the developed nanoplatform could induce mitochondrial dysfunction and elevated cell apoptosis, resulting in highly efficient anti-tumor outcomes in vitro . Collectively, the combined design principles adopted for carrier-free nanodrugs construction in this study aimed at targeting different intracellular organelles for facilitating ROS production and DNA disruption can be extended to other carrier-free nanodrugs-dependent therapeutic systems.